کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5891795 | 1153281 | 2011 | 8 صفحه PDF | دانلود رایگان |
To elucidate the histological events that follow administration of eldecalcitol, a second-generation of vitamin D analog currently awaiting approval as a drug for treatment of osteoporosis, we employed the ovariectomy (OVX) rat model. OVX rats received vehicle or 30Â ng/kg of eldecalcitol, and sham-operated animals received vehicle only. Rats were sacrificed after 12Â weeks and had their femora and tibiae removed and processed for histochemical and histomorphometrical analyses. When compared with OVX group, osteoclastic number and bone resorption parameters were significantly reduced in eldecalcitol-treated rats, accompanied by decreased bone formation parameters. The preosteoblastic layer, with which osteoclastic precursors interact for mutual differentiation, was poorly developed in the eldecalcitol group, indicating less cell-to-cell contact between preosteoblasts and osteoclast precursors. Interestingly, eldecalcitol did promote a type of focal bone formation that is independent of bone resorption, a process known as bone minimodeling. While the number of ED-1-positive macrophages was higher in the bone marrow of treated rats, though osteoclastic number was deceased. Taken together, our findings suggest that eldecalcitol stimulates preosteoblastic differentiation rather than their proliferation, which in turn may prevent or diminish cell-to-cell contact between preosteoblasts and osteoclastic precursors, and therefore, lead to lower osteoclast numbers and decreased bone resorption.
⺠We examined bones of OVX rats and eldecalcitol-administered OVX rats. ⺠Eldecalcitol appears to affect osteoblastic differentiation and focal bone formation (mini-modeling) instead of stimulating preosteoblastic proliferation. ⺠The treatment with eldecalcitol lowers osteoclast number and diminishes osteoclastic activity/functionality, mediating less interaction with preosteoblastic cells. ⺠Eldecalcitol administration may favor the macrophage differentiation cascade on the expense of cells that would otherwise become osteoclasts.
Journal: Bone - Volume 49, Issue 3, September 2011, Pages 335-342